Questcor Pharmaceuticals Inc (QCOR)

pos +1.52
Today's Range: 92.17 - 94.42 | QCOR Avg Daily Volume: 1,566,300
Last Update: 08/14/14 - 4:00 PM EDT
Volume: 3,178,792
YTD Performance: 71.90%
Open: $92.93
Previous Close: $92.08
52 Week Range: $47.71 - $97.80
Oustanding Shares: 61,448,937
Market Cap: 5,748,999,329
6-Month Chart
TheStreet Ratings Grade for QCOR
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 0 1 1 1
Moderate Buy 0 0 0 0
Hold 5 4 4 3
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 3.00 2.60 2.60 2.50
Latest Dividend: 0.30
Latest Dividend Yield: 1.28%
Dividend Ex-Date: 06/27/14
Price Earnings Ratio: 16.10
Price Earnings Comparisons:
QCOR Sector Avg. S&P 500
16.10 16.40 28.24
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
7.39% 38.91% 196.58%
Revenue 56.90 5.94 0.90
Net Income 48.00 7.34 1.01
EPS 51.90 7.91 1.06
Earnings for QCOR:
Revenue 0.80B
Average Earnings Estimates

Earnings Estimates data is not available for QCOR.

Chart Benchmark
Average Frequency Timeframe
Indicator Chart Scale  
Symbol Comparison Bollinger Bands
Even among the losers, buys are scarce.
I can't remember the last time a company got more than a slap on the wrist. 
A wave of M&A in the health sector makes sense.
But in the real world they're wrong, as the Questcor buyout demonstrates.

Off the Charts Real Money Pro($)

America Movil is showing significant relative weakness this year.
Oct 30, 2013 | 7:58 AM EDT
QCOR raised its numbers, according to Jefferies. Very robust Acthar growth  in rheumatology. $76 price target and Buy rating.
Aug 21, 2013 | 7:25 AM EDT
QCOR was upgraded from Neutral to Buy, Bank of America/Merrill Lynch said. $80 price target. Acthar sales are driving growth. 
Jul 31, 2013 | 8:36 AM EDT
QCOR was upgraded from Neutral to Overweight, Piper Jaffray said. $74 price target. Acthar can drive near-term growth. 
Jun 21, 2013 | 7:47 AM EDT
QCOR was downgraded from Buy to Neutral, Bank of America/Merrill Lynch said. $51 price target. Acthar could face increased competition....
Jun 21, 2013 | 7:25 AM EDT
QCOR was upgraded from Perform to Outperform, Oppenheimer said. $57 price target. New analyst believes that Acthar can drive near-term ...

Columnist Conversations

Stock has been roasted last five trading sessions. Time to rotate into Ford ahead of big CEO long-term plan re...
Equity futures were up slightly just before 9:30 PM Sunday night.
Spent a good amount of time with PayPal CEO Dan Schulman this week...and came away fully understanding why thi...
Has quietly taken a mini beating over the past few weeks. Might be worth a look on Monday given everything tha...


News Breaks

Powered by


Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.